Webinar :Register now for webinar on 'Trade BankNifty in just 15 minutes a day' - By Asmita Patel

COVID-19 impact: Consumer durable sector face earnings downgrades

Edelweiss slashed earnings by 9–18 percent for stocks in their coverage. It remains positive on Amber Enterprises which was recently added to the model portfolio along with KEI Industries, and Voltas.
Mar 31, 2020 / 01:54 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

After three good years of healthy double-digit growth, the past 2–3 quarters have been one of deceleration led by slowing infra and weakening disposable income profiles in the consumer durable sector.

The COVID-19-led disruption will add to sector woes since: i) channel appetite is already low; ii) infra spend outlook for FY21 remains subdued; and iii) weaker retail off-take implies consensus estimates are at risk, Edelweiss Securities said in a report.

The report also suggests that large players are trading at rich valuations. For FY21, it expects lower growth across segment vis-à-vis their respective long-term growth rates).

The brokerage firm slashed earnings by 9–18 percent for stocks in their coverage. It remains positive on Amber Enterprises which was recently added to the model portfolio along with KEI Industries, and Voltas.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Valuation 30 March

Growth across players has come off over the past few quarters barring cooling products, reflecting the impact of weak infra, lower retail demand and deteriorating distribution channel health.

Top-line growth, particularly in electrical segments (excluding large appliances) has tapered to 6 percent (Q3FY20) which is lower than the five-year CAGR of 12 percent, said the report.

The recent stock correction to some extent factor near term earnings disruption from COVID-19 and valuation correction has been in line with broader indices.

But, the current scenario, in contrast, poses multiple challenges, implying a more enduring effect on demand potentially extending to medium term (12-18 months).

“It is possible that rich valuations do pose challenges as most stocks in the coverage are still trading at mid-cycle/lower end of the peak cycle. Only a few possess levers to outperform in a tough demand outlook,” said the report.

Out of the coverage universe, Edelweiss Securities reiterated their conviction for: a) Voltas - sustained leadership in RACs and potential to scale up the refrigerator business (JV), b) KEI - earnings growth resilience and balance sheet discipline.

Consumer Durable industry

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Moneycontrol News

stay updated

Get Daily News on your Browser
Sections